HMGCS2
Basic information
Region (hg38): 1:119748002-119768905
Links
Phenotypes
GenCC
Source:
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (Definitive), mode of inheritance: AR
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (Strong), mode of inheritance: AR
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (Strong), mode of inheritance: AR
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (Supportive), mode of inheritance: AR
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency | AR | Biochemical | Specific dietary measures (especially avoidance of fasting) as well as other treatments may be beneficial, both in well and decompensated state | Biochemical; Neurologic | 9337379; 9727719; 11228257; 11479731; 16601895 |
ClinVar
This is a list of variants' phenotypes submitted to
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (19 variants)
- not provided (2 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HMGCS2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 49 | 49 | ||||
missense | 102 | 115 | ||||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 9 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 7 | |||||
splice region | 4 | 4 | 1 | 9 | ||
non coding | 37 | 23 | 65 | |||
Total | 20 | 16 | 107 | 87 | 23 |
Highest pathogenic variant AF is 0.0000920
Variants in HMGCS2
This is a list of pathogenic ClinVar variants found in the HMGCS2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-119748025-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Benign (Apr 27, 2017) | ||
1-119748055-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Benign (Apr 27, 2017) | ||
1-119748082-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-119748515-T-G | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency • PHGDH deficiency | Likely benign (Jun 14, 2016) | ||
1-119748606-TTTCACAAA-T | Likely benign (Jul 24, 2020) | |||
1-119748682-G-A | PHGDH deficiency • 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Likely benign (Jun 14, 2016) | ||
1-119748692-G-A | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Uncertain significance (Jan 13, 2018) | ||
1-119748708-G-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Uncertain significance (Jan 12, 2018) | ||
1-119748769-T-C | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Likely benign (Jan 13, 2018) | ||
1-119748835-T-G | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Benign (Apr 27, 2017) | ||
1-119748848-TAAAC-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Uncertain significance (Jun 14, 2016) | ||
1-119748857-A-G | not specified | Benign (Apr 04, 2014) | ||
1-119750546-T-C | Benign (Jul 27, 2018) | |||
1-119750729-T-C | Benign (Jun 29, 2018) | |||
1-119750744-T-C | Benign (Jun 23, 2018) | |||
1-119750771-C-G | Likely benign (Jun 23, 2018) | |||
1-119750807-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency • HMGCS2-related disorder | Conflicting classifications of pathogenicity (Jan 01, 2024) | ||
1-119750808-G-A | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Likely benign (Dec 31, 2022) | ||
1-119750812-C-T | Inborn genetic diseases | Uncertain significance (Feb 11, 2022) | ||
1-119750813-G-A | Inborn genetic diseases | Uncertain significance (Dec 14, 2022) | ||
1-119750815-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency • not specified | Uncertain significance (Jul 16, 2024) | ||
1-119750816-G-A | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency • Inborn genetic diseases | Uncertain significance (Mar 26, 2024) | ||
1-119750827-C-G | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Pathogenic/Likely pathogenic (Mar 02, 2023) | ||
1-119750830-C-T | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Pathogenic/Likely pathogenic (May 27, 2022) | ||
1-119750831-G-A | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | Uncertain significance (Jan 24, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HMGCS2 | protein_coding | protein_coding | ENST00000369406 | 9 | 20910 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.34e-14 | 0.0899 | 125647 | 0 | 101 | 125748 | 0.000402 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.191 | 289 | 280 | 1.03 | 0.0000170 | 3278 |
Missense in Polyphen | 111 | 125.48 | 0.8846 | 1489 | ||
Synonymous | -1.63 | 132 | 110 | 1.20 | 0.00000617 | 1043 |
Loss of Function | 0.736 | 23 | 27.1 | 0.848 | 0.00000175 | 280 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00143 | 0.00143 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000435 | 0.000435 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000248 | 0.000246 |
Middle Eastern | 0.000435 | 0.000435 |
South Asian | 0.00111 | 0.00111 |
Other | 0.000489 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase.;
- Disease
- DISEASE: 3-hydroxy-3-methylglutaryl-CoA synthase-2 deficiency (HMGCS2D) [MIM:605911]: A metabolic disorder characterized by severe hypoketotic hypoglycemia, encephalopathy, and hepatomegaly. {ECO:0000269|PubMed:11228257, ECO:0000269|PubMed:11479731, ECO:0000269|PubMed:12647205}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Butanoate metabolism - Homo sapiens (human);Synthesis and degradation of ketone bodies - Homo sapiens (human);Terpenoid backbone biosynthesis - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);3-Methylglutaconic Aciduria Type I;Valine, Leucine and Isoleucine Degradation;2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;Isovaleric Aciduria;3-Methylcrotonyl Coa Carboxylase Deficiency Type I;Propionic Acidemia;Maple Syrup Urine Disease;3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency;Isobutyryl-coa dehydrogenase deficiency;3-hydroxyisobutyric aciduria;3-hydroxyisobutyric acid dehydrogenase deficiency;Isovaleric acidemia;Methylmalonate Semialdehyde Dehydrogenase Deficiency;Succinyl CoA: 3-ketoacid CoA transferase deficiency;Methylmalonic Aciduria;3-Methylglutaconic Aciduria Type IV;3-Methylglutaconic Aciduria Type III;Ketone Body Metabolism;Butyrate Metabolism;Beta-Ketothiolase Deficiency;Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha);Synthesis and Degradation of Ketone Bodies;Amino Acid metabolism;PPAR signaling pathway;Liver steatosis AOP;ketogenesis;Butanoate metabolism;Metabolism of lipids;Metabolism;superpathway of cholesterol biosynthesis;Synthesis of Ketone Bodies;Ketone body metabolism;Butanoate metabolism;Valine Leucine Isoleucine degradation;Validated targets of C-MYC transcriptional repression;mevalonate pathway;superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
(Consensus)
Recessive Scores
- pRec
- 0.279
Intolerance Scores
- loftool
- 0.194
- rvis_EVS
- -0.87
- rvis_percentile_EVS
- 10.73
Haploinsufficiency Scores
- pHI
- 0.200
- hipred
- N
- hipred_score
- 0.219
- ghis
- 0.546
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.965
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hmgcs2
- Phenotype
Gene ontology
- Biological process
- acetyl-CoA metabolic process;cholesterol biosynthetic process;farnesyl diphosphate biosynthetic process, mevalonate pathway;regulation of lipid metabolic process;ketone body biosynthetic process
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- hydroxymethylglutaryl-CoA synthase activity